Investigation of GLP1-Receptor Agonists in Men With Prostate Cancer Taking Androgen Deprivation Therapy

To be considered for this study, you need to have a diagnosis of prostate cancer and currently be receiving, or about to start, hormone therapy for it. You also need to have an elevated Body Mass Index (BMI). This means your BMI should be 30 or higher. If your BMI is 27 or higher, you might still be eligible if you also have at least one of these conditions: high blood pressure, type 2 diabetes, sleep apnea (breathing stops during sleep), or high cholesterol.

However, there are certain reasons why you wouldn't be able to join. For example, if you have type 1 diabetes, are already taking a similar type of drug called a GLP-1 RA, or are under 18 years old, you wouldn't be able to participate. Also, if you have a history of inflammation of the pancreas (pancreatitis) or certain types of thyroid cancer in yourself or your family, or a specific genetic condition called Multiple Endocrine Neoplasia type 2, you would not be eligible. The study is only for men.

If you meet the requirements and decide to take part, you'll first have a 'baseline' visit where initial health checks are done. You'll then start taking Semaglutide, which is given once a week using a pen injector under the skin. The dose will start low and gradually increase over the first few months until it reaches the study's full dose. If you experience any side effects, the study team might lower your dose to one that you can better tolerate.

Throughout the study, you'll have several follow-up appointments. This includes a phone call one month after you start, then in-person visits at 3 months, 6 months, and a final visit at 12 months (the 'Close-out' visit). These visits are for monitoring your health, checking how you're feeling, and seeing how the medication is affecting things like your weight, blood sugar, and blood pressure. The total duration of your participation in the trial would be 12 months.